Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPH037668B2 - - Google Patents
[go: Go Back, main page]

JPH037668B2 - - Google Patents

Info

Publication number
JPH037668B2
JPH037668B2 JP62082787A JP8278787A JPH037668B2 JP H037668 B2 JPH037668 B2 JP H037668B2 JP 62082787 A JP62082787 A JP 62082787A JP 8278787 A JP8278787 A JP 8278787A JP H037668 B2 JPH037668 B2 JP H037668B2
Authority
JP
Japan
Prior art keywords
amlodipine
composition
benzenesulfonate
composition according
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP62082787A
Other languages
English (en)
Other versions
JPS62240660A (ja
Inventor
Deeuison Edowaado
Inguramu Ueeruzu Jeemuzu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH037668(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of JPS62240660A publication Critical patent/JPS62240660A/ja
Publication of JPH037668B2 publication Critical patent/JPH037668B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)

Description

【発明の詳細な説明】
産業上の利用分野 本発明は、改良されたアムロジピン
（amlodipine）の製剤用塩およびその薬剤組成物
に関する。 従来の技術 化合物アムロジピン〔２−（２−アミノエトキ
シメチル）−４−（２−クロルフエニル）−１，４
−ジヒドロ−６−メチルピリジン−３，５−ジカ
ルボン酸 ３−エチル ５−メチル〕は、抗虚血
および抗高血圧剤としての有用性を有する強力で
持効性のカルシウム通路（channel）遮断薬であ
る。 ヨーロツパ特許出願公開第89167号には、数種
の異なつたアムロジピンの薬学的に受容できる塩
形が記載されている。特に、薬学的に受容できる
酸付加塩は、塩酸塩、臭化水素酸塩、硫酸塩、燐
酸塩または酸性燐酸塩、酢酸塩、マレイン酸塩、
フマール酸塩、乳酸塩、酒石酸塩、クエン酸塩お
よびグルコン酸塩のような、薬学的に受容できる
陰イオンを含有する無毒性酸付加塩を形成する酸
から形成されるものであると述べられている。こ
れらの塩のうち、マレイン酸塩は、特に好ましい
ものとして記載されている。 発明が解決しようとする問題点 今回予想外のことに、ベンゼンスルホン酸塩
（以下、ベシレート塩と呼ぶ）が、アムロジピン
の公知の塩を凌ぐ数多くの利点を有し、さらに、
予想外にも、それをアムロジピンの薬剤処方物の
製造に特に適するものとする優れた処方特性の独
特の組み合わせを有することがわかつた。 従つて、本発明に従えば、アムロジピンのベシ
レート塩が提供される。 別の観点においては、本発明は、アムロジピン
のベシレート塩ならびに薬学的に受容できる希釈
剤またはキヤリヤーの薬剤組成物を提供する。 本発明はさらに、賦形剤と混合したアムロジピ
ンのベシレート塩より成る錠剤処方物を提供す
る。好ましい処方物は、上記ベシレート塩、微結
晶性セルロースのような圧縮助剤、無水第二燐残
カルシウムのような錠剤に光沢を与えるための添
加物、澱粉グリコール酸ナトリウムのような崩解
剤およびステアリン酸マグネシウムのような潤滑
剤を含む。 さらに、本発明は、賦形剤と混合したアムロジ
ピンのベシレート塩より成るカプセル剤処方物を
提供する。好ましい処方物は、上記ベシレート
塩、不活性希釈剤、乾燥した崩解剤および上記し
たような潤滑剤を含有する。 本発明はさらに、非経口投与用の、アムロジピ
ンのベシレート塩の無菌水溶液を提供する。好ま
しくは、このような溶液は、10ないし40容量％の
プロピレングリコールを含有し、好ましくは、溶
血を避けるのに十分な、例えば約１％Ｗ／Ｖの塩
化ナトリウムをも含有する。 本発明はまた、ヒトにおける虚血性心臓病、特
に狭心症、または高血圧症を治療するのに使用す
るためのアムロジピンのベシレート塩をも提供す
る。 本発明はまた、アムロジピン塩基を、不活性溶
媒中のベンゼンスルホン酸またはそのアンモニウ
ム塩の溶液と反応させ、アムロジピンのベシレー
ト塩を回収することによる、アムロジピンのベシ
レート塩を製造する方法をも提供する。 好ましい不活性溶媒は、工業用メタノールで変
性したアルコールである。 問題を解決するための手段 アムロジピンは遊離塩基として有効であるけれ
ども、実際には、これは、薬学的に受容できる酸
との塩の形で投与するのが最もよい。この目的に
適するためには、この薬学的に受容できる塩は、
次の４つの生理化学的判定基準：(1)良好な溶解
性；(2)良好な安定性；(3)非吸湿性；(4)錠剤処方の
ための加工性；などを満足しなくてはならない。 上に略述した塩の多くはこれらの判定基準のい
くつかを満足するけれども、どれも、それらをす
べて満足はせず、好ましいマレイン酸塩でさえ、
優れた溶解性を示すけれども数週間後には溶液中
で分解する傾向がある。したがつて、本発明者ら
は一連のアムロジピンの薬学的に受容できる塩類
を製造し、次の判定基準を用いて評価した： １ 一般に、良好な生物学的利用能のためには、
良好な水溶性が必要であることは、当技術分野
では公知である。注射液を処方するにはさらに
高い溶解度が必要とされるけれども、通常はPH
１−7.5で１mgml-1より大きい溶解度が求めら
れる。さらに、血液のPH（7.4）に近いPHを有
する溶液を与える塩は、それらが容易に生体に
適合することができ、しかもその溶解度を変え
ることなく簡単に必要なPH領域に緩衝化される
ことができるため、好ましい。 下記の比較データからわかるように、アムロ
ジピンのベシレート塩は他の塩に比べて良好な
溶解度特性を示す。
【表】 ２ 固体状態における良好な安定性は、錠剤およ
びカプセル剤に対して非常に重要であり、一方
溶液における良好な安定性は水性注射液につい
て要求される。 化学的安定性について選別するために、各々
の塩を粉末ビヒクル中に配合し、錠剤またはカ
プセル剤の形にした。錠剤の場合にはビヒクル
は、無水第二燐酸カルシウムと50：50で組み合
わせた微結晶性セルロースより成つていた。カ
プセル剤の場合は、ビヒクルは、マニトールと
乾燥とうもろこし澱粉との４：１組み合わせ物
より成つていた。次に、これらを50および75℃
で密封バイアル中で３週間までの間貯蔵した。
薬剤およびすべての分解生成物を、メタノー
ル：クロロホルム（50：50）で抽出し、種々の
溶媒系を用いてシリカ薄層クロマトグラフイー
（tlc）板上に分離した。 その結果を比較し、各塩を生成された分解生
成物の数および量に従つて並べた。 結果を比較することにより、次の順番が明ら
かになつたが、これによればベシレートが最も
安定な塩であり、塩酸塩が最も安定性の小さい
塩である。
【表】 酢酸塩 ↓
塩酸塩 不安定

Claims (1)

  1. 【特許請求の範囲】 １ アムロジピン〔２−（２−アミノエトキシメ
    チル）−４−（２−クロルフエニル）−１，４−ジ
    ヒドロ−６−メチルピリジン−３，５−ジカルボ
    ン酸 ３−エチル ５−メチル〕のベンゼンスル
    ホン酸塩。 ２ アムロジピンのベンゼンスルホン酸塩を有効
    成分とする、心臓病または高血圧治療用の薬剤組
    成物。 ３ 賦形剤と混合したアムロジピンのベンゼンス
    ルホン酸塩より成る錠剤である特許請求の範囲第
    ２項記載の組成物。 ４ 賦形剤が、圧縮助剤、錠剤に光沢を与えるた
    めの添加物、崩解剤および潤滑剤より成る、特許
    請求の範囲第３項に記載の組成物。 ５ 賦形剤が、微結晶性セルロース、無水第二燐
    酸カルシウム、澱粉グリコール酸ナトリウムおよ
    びステアリン酸マグネシウムより成る、特許請求
    の範囲第４項に記載の組成物。 ６ 賦形剤と混合したアムロジピンのベンゼンス
    ルホン酸塩より成るカプセル剤である特許請求の
    範囲第２項記載の組成物。 ７ 賦形剤が不活性希釈剤、乾燥崩解剤および潤
    滑剤より成る、特許請求の範囲第６項に記載の組
    成物。 ８ 賦形剤が、微結晶性セルロース、乾燥とうも
    ろこし澱粉またはステアリン酸マグネシウムより
    成る、特許請求の範囲第６項記載の組成物。 ９ 非経口的投与用の、アムロジピンのベンゼン
    スルホン酸塩を含む無菌水溶液である、特許請求
    の範囲第２項記載の組成物。 １０ 10ないし40％Ｗ／Ｖのプロピレングリコー
    ルを含む特許請求の範囲第９項に記載の組成物。 １１ 約１％Ｗ／Ｖ塩化ナトリウムを含む特許請
    求の範囲第９または第１０項に記載の組成物。
JP62082787A 1986-04-04 1987-04-03 アムロジピンのベンゼンスルホン酸塩 Granted JPS62240660A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868608335A GB8608335D0 (en) 1986-04-04 1986-04-04 Pharmaceutically acceptable salts
GB8608335 1986-04-04

Publications (2)

Publication Number Publication Date
JPS62240660A JPS62240660A (ja) 1987-10-21
JPH037668B2 true JPH037668B2 (ja) 1991-02-04

Family

ID=10595731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62082787A Granted JPS62240660A (ja) 1986-04-04 1987-04-03 アムロジピンのベンゼンスルホン酸塩

Country Status (47)

Country Link
US (1) US4879303A (ja)
EP (1) EP0244944B1 (ja)
JP (1) JPS62240660A (ja)
KR (1) KR950006710B1 (ja)
CN (1) CN1023800C (ja)
AP (1) AP50A (ja)
AR (1) AR242562A1 (ja)
AT (1) ATE49752T1 (ja)
BE (1) BE1000130A4 (ja)
BG (1) BG60698B2 (ja)
CA (1) CA1321393C (ja)
CS (1) CS265237B2 (ja)
CY (1) CY1669A (ja)
CZ (1) CZ289095B6 (ja)
DD (1) DD265142A5 (ja)
DE (2) DE3710457A1 (ja)
DK (1) DK171708B1 (ja)
EC (1) ECSP941129A (ja)
EG (1) EG18266A (ja)
ES (2) ES2012803B3 (ja)
FI (1) FI85017C (ja)
FR (1) FR2596758B1 (ja)
GB (2) GB8608335D0 (ja)
GR (2) GR870525B (ja)
HK (1) HK76092A (ja)
HU (1) HU196962B (ja)
IE (1) IE59457B1 (ja)
IL (1) IL82101A (ja)
IN (1) IN168414B (ja)
IT (1) IT1203853B (ja)
LU (1) LU86812A1 (ja)
MA (1) MA20938A1 (ja)
MX (1) MX5847A (ja)
MY (1) MY101177A (ja)
NL (1) NL8700791A (ja)
NO (1) NO172181C (ja)
NZ (1) NZ219868A (ja)
PH (1) PH24348A (ja)
PL (1) PL149532B1 (ja)
PT (1) PT84611B (ja)
SE (1) SE463457B (ja)
SG (1) SG59692G (ja)
SK (1) SK278435B6 (ja)
SU (1) SU1498388A3 (ja)
UA (1) UA6344A1 (ja)
YU (1) YU44801B (ja)
ZA (1) ZA872439B (ja)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
EP1013275A3 (en) * 1991-11-26 2001-01-10 Sepracor, Inc. Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
AT399718B (de) * 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US5389654A (en) * 1992-11-26 1995-02-14 Lek, Tovarna, Farmacevtskih In Kemicnih . . . 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
SI9200344B (sl) * 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO1996028185A2 (en) 1995-03-16 1996-09-19 Pfizer Inc. Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor
HU221810B1 (hu) * 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
AU6767198A (en) * 1998-03-26 1999-05-03 Dr. Reddy's Laboratories Limited Stable pharmaceutical composition containing amlodipine besylate and atenol ol
RU2188636C2 (ru) * 1998-03-26 2002-09-10 Др. Редди'С Лабораторис Лтд. Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
PL189666B1 (pl) * 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
TR200100062T2 (tr) 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
UA33033A (uk) * 1998-10-16 2001-02-15 Др.Редіс Леборетрис Лтд Спосіб одержання безилату амлодипіну
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
RU2142942C1 (ru) * 1999-04-28 1999-12-20 Дж. Б.Кемикалс энд Фармасьютикалс Лтд. Способ получения монобензолсульфоната 3-этил-5-метилового эфира 2-[(2-аминоэтокси)метил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5-пиридинди карбоновой кислоты
EP1180102B9 (en) 1999-05-27 2005-03-02 Pfizer Products Inc. Mutual prodrugs of amlodipine and atorvastatin
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
RU2161156C1 (ru) * 1999-06-01 2000-12-27 Джи.Б.Кемикалс Энд Фармасьютикалс Лтд Способ получения 3-этил-5-метиловый эфир 2-[2-(n-фталимидо)-этоксиметил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5- пиридиндикарбоновой кислоты
UA72768C2 (en) * 1999-07-05 2005-04-15 Richter Gedeon Vegyeszet A method for obtaining amilodipine benzenesulphonate
RU2146672C1 (ru) * 1999-10-13 2000-03-20 Др.Редди'С Лабораторис Лтд. Способ получения 3-этил-5-метил(±)2[2-аминоэтокси)-метил]-4-(2-хлорфенил)-1,4-дигидро- 6-метил-3,5-пиридиндикарбоксилат монобензолсульфоната
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
AU2001283085A1 (en) 2000-08-04 2002-02-18 R. Preston Mason Synergistic effect of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
EP1309556B1 (en) 2000-12-29 2004-11-24 Pfizer Limited Amlodipine fumarate
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
CA2433193C (en) 2000-12-29 2006-01-31 Pfizer Limited Amide derivative of amlodipine
WO2002053540A1 (en) * 2000-12-29 2002-07-11 Pfizer Limited Aspartate derivative of amlodipine as calcium channel antagonist
EP1309557B9 (en) 2000-12-29 2006-11-15 Pfizer Limited Amlodipine hemimaleate
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
PL362660A1 (en) * 2000-12-29 2004-11-02 Pfizer Limited Process for making amlodipine maleate
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
WO2002054062A2 (en) * 2000-12-29 2002-07-11 Pfizer Limited Reference standards and processes for determining the purity or stability of amlodipine maleate
DE50112189D1 (de) * 2001-01-09 2007-04-26 Siegfried Generics Int Ag Salze von Amlodipin-Mesylat
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
US20030027848A1 (en) * 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
DE60235101D1 (de) * 2001-07-06 2010-03-04 Lek Pharmaceuticals Verfahren zur herstellung hochreines amlodipinbenzolsulfonat
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
AR037565A1 (es) * 2001-11-21 2004-11-17 Synthon Bv Formas de sales de amlodipina y procedimientos para prepararlas.
HU226642B1 (en) * 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
JP4287752B2 (ja) * 2002-04-13 2009-07-01 ハンリム ファーマシューティカル カンパニー リミテッド アムロジピンニコチネート及びその製造方法
JP4801348B2 (ja) 2002-05-06 2011-10-26 エンドサイト，インコーポレイテッド ビタミンを標的とした造影剤
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SI21233A (sl) * 2002-05-31 2003-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Kristalni hidratni obliki amlodipin benzensulfonata visoke čistote, postopki za njuno pripravo in uporaba
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
RU2221784C1 (ru) * 2002-07-05 2004-01-20 Марвел Лайфсайнсез Прайвит Лимитед Способ получения бензолсульфоната амлодипина
KR100496436B1 (ko) * 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR20040011751A (ko) * 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) * 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
KR100582141B1 (ko) 2002-08-29 2006-05-22 다이쇼 세이야꾸 가부시끼가이샤 4-플루오로-2-시아노피롤리딘 유도체 벤젠술폰산염
US6784297B2 (en) * 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
US7279492B2 (en) 2002-09-11 2007-10-09 Hanlim Pharmaceutical Co., Ltd. S-(−)-amlodipine nicotinate and process for the preparation thereof
AU2003253460A1 (en) * 2002-09-19 2004-04-08 Cj Corporation Crystalline organic acid salt of amlodipine
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
EP1407773A1 (en) * 2002-10-08 2004-04-14 Council of Scientific and Industrial Research A process for the preparation of s (-) amlodipine salts
US20040072879A1 (en) * 2002-10-10 2004-04-15 Dr. Reddy's Laboratories Limited Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
AU2002368531A1 (en) * 2002-12-30 2004-07-22 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Isolation of dihydropyridine derivative and preparation salts thereof
EP1587792B1 (en) 2003-01-27 2014-08-27 Hanmi Science Co., Ltd. Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof
KR20120058618A (ko) * 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
KR20040072363A (ko) * 2003-02-12 2004-08-18 주식회사 대웅 신규한 암로디핀 사이클라메이트 염 및 그의 제조방법
WO2004075825A2 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Dosage forms of amlodipine and processes for their preparation
ES2531088T3 (es) 2003-04-25 2015-03-10 Cadila Healthcare Ltd Sales de clopidogrel y procedimiento de preparación
GB2415696B (en) * 2003-04-25 2007-06-20 Cipla Ltd Process for preparing amlodipine mesylate monohydrate
WO2004103960A2 (en) * 2003-05-16 2004-12-02 Ambit Biosciences Corporation Compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
EA009646B1 (ru) 2003-05-30 2008-02-28 Рэнбакси Лабораториз Лтд. Замещённые производные пиррола и их применение в качестве ингибиторов hmg-coa
RU2239433C1 (ru) * 2003-06-09 2004-11-10 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая вазодилатирующим, антиангинальным, гипотензивным и спазмолитическим действием, и способ ее изготовления
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
WO2005042485A1 (en) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Acid added salts of amlodipine
KR100841409B1 (ko) * 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030602A1 (en) * 2004-03-16 2006-02-09 Sepracor Inc. (S)-amlodipine malate
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
DE602005019582D1 (de) * 2004-08-30 2010-04-08 Seo Hong Yoo Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
KR20070084211A (ko) * 2004-10-15 2007-08-24 유서홍 약제학적 화합물의 독성을 감소시키기 위한 방법 및 조성물
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
EP1833466A1 (en) * 2004-12-28 2007-09-19 Ranbaxy Laboratories Limited Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
CA2610838A1 (en) * 2005-06-07 2006-12-14 Ramot At Tel Aviv University Ltd. Novel salts of conjugated psychotropic drugs and processes of preparing same
CA2613417C (en) * 2005-06-27 2011-11-29 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DE602005005706T2 (de) * 2005-09-28 2009-04-16 Teva Pharmaceutical Industries Ltd. Stabile Arzneimittelkombinationen von Amlodipinbesylat und Benazeprilhydrochlorid
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
WO2008010223A2 (en) 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
KR100795313B1 (ko) 2006-09-05 2008-01-21 현대약품 주식회사 암로디핀 베실레이트를 포함하는 약학 조성물
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor
CN101167724B (zh) * 2006-10-25 2012-08-22 北京华安佛医药研究中心有限公司 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
CA2673336A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
CN105152983A (zh) 2007-01-29 2015-12-16 韩诺生物制药株式会社 N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2009032286A2 (en) 2007-09-06 2009-03-12 Nektar Therapeutics Al, Corporation Oligomer-calcium channel blocker conjugates
US8143314B1 (en) * 2007-09-13 2012-03-27 Robert Carl Stover Methods and formulations for treating ineffective or decreased esophageal motility
CN101855204B (zh) * 2007-09-21 2013-09-11 韩兀生物制药株式会社 N,n-二甲基亚氨二羰酸二酰胺二羧酸盐、其制备方法及其药物组合物
JP2011507973A (ja) 2007-12-31 2011-03-10 ルピン・リミテッド アムロジピンとバルサルタンとの医薬組成物
US8207369B2 (en) 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
RU2359672C1 (ru) * 2008-02-18 2009-06-27 Зао "Биоком" Твердая лекарственная форма, предназначенная для лечения артериальной гипертензии и стенокардии, и способ ее получения
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
CN102256604A (zh) * 2008-12-17 2011-11-23 株式会社医药处方 稳定的氨氯地平含水口服制剂
MA33056B1 (fr) 2009-01-23 2012-02-01 Hanmi Holding Co Ltd Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
WO2011056240A2 (en) * 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
EP2509603A1 (en) 2009-12-09 2012-10-17 Biolinerx Ltd. Methods of improving cognitive functions
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
CA2789654A1 (en) 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
WO2011117876A1 (en) 2010-03-26 2011-09-29 Fdc Limited An improved process for the preparation of amlodipine free base and acid addition salts thereof
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
MX336875B (es) * 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
EP2635284B1 (en) 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
WO2012071524A1 (en) * 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
CA2866852C (en) 2012-03-15 2020-12-29 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
BR112014022790B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
US20150374713A1 (en) 2013-02-08 2015-12-31 Wockhardt Limited Stable pharmeceutical composition of amlodipine and benazepril or salts thereof
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
CN104523588A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-硬脂酸离子液体及其制备方法和用途
CN104529877A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-癸酸离子液体及其制备方法和用途
WO2017030893A1 (en) 2015-08-14 2017-02-23 Endocyte, Inc. Method of imaging with a chelating compound
US20180303811A1 (en) 2015-10-23 2018-10-25 Ftf Pharma Private Limited Oral solution of dihydropyridine derivatives
CN105395495A (zh) * 2015-11-30 2016-03-16 宜昌东阳光长江药业股份有限公司 一种含有苯磺酸氨氯地平的组合物及其制备方法
EP3219309A1 (en) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
JP6411662B2 (ja) 2016-05-30 2018-10-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 固定容量配合剤
EP3960158B1 (en) 2016-10-07 2025-05-21 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP3501502A1 (en) 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
WO2019200143A1 (en) 2018-04-11 2019-10-17 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
WO2019241519A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine
EP4052695A1 (en) 2021-03-05 2022-09-07 Midas Pharma GmbH Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil
EP4370101A1 (en) 2021-07-15 2024-05-22 Adamed Pharma S.A. A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816612A (en) * 1967-03-23 1974-06-11 Degussa Process for the production of basically reacting pharmaceuticals
US4032637A (en) * 1972-09-26 1977-06-28 Sandoz Ltd. Method of promoting sleep
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
ZA839187B (en) * 1982-12-10 1984-07-25 Ciba Geigy Ag Amide compounds

Also Published As

Publication number Publication date
SE8701348L (sv) 1987-10-05
EP0244944A3 (en) 1988-01-07
CY1669A (en) 1993-05-14
EG18266A (en) 1992-12-30
PL149532B1 (en) 1990-02-28
FI85017B (fi) 1991-11-15
MA20938A1 (fr) 1987-12-31
CN87102493A (zh) 1987-10-14
EP0244944B1 (en) 1990-01-24
ES2002599A6 (es) 1988-08-16
GB8608335D0 (en) 1986-05-08
EP0244944A2 (en) 1987-11-11
FR2596758A1 (fr) 1987-10-09
AU7103087A (en) 1987-10-08
PL264982A1 (en) 1988-05-26
HUT43821A (en) 1987-12-28
HK76092A (en) 1992-10-09
PT84611B (pt) 1989-11-30
NO871408L (no) 1987-10-05
ZA872439B (en) 1988-11-30
MX5847A (es) 1993-08-01
SE8701348D0 (sv) 1987-03-31
BE1000130A4 (fr) 1988-04-12
SG59692G (en) 1992-12-04
DK170187D0 (da) 1987-04-03
CS353991A3 (en) 1992-04-15
GB8707653D0 (en) 1987-05-07
FR2596758B1 (fr) 1988-12-02
ECSP941129A (es) 1994-12-15
IT1203853B (it) 1989-02-23
PH24348A (en) 1990-06-13
IN168414B (ja) 1991-03-30
AP50A (en) 1989-09-16
IE59457B1 (en) 1994-02-23
CS265237B2 (en) 1989-10-13
AP8700060A0 (en) 1987-02-01
YU58087A (en) 1988-08-31
SU1498388A3 (ru) 1989-07-30
DD265142A5 (de) 1989-02-22
JPS62240660A (ja) 1987-10-21
SE463457B (sv) 1990-11-26
HU196962B (en) 1989-02-28
MY101177A (en) 1991-07-31
GB2188630B (en) 1990-04-04
ES2012803B3 (es) 1990-04-16
IT8719977A0 (it) 1987-04-03
CZ289095B6 (cs) 2001-10-17
GR3000394T3 (en) 1991-06-07
CS236387A2 (en) 1989-01-12
CN1023800C (zh) 1994-02-16
US4879303A (en) 1989-11-07
SK278435B6 (en) 1997-05-07
GR870525B (en) 1987-08-12
FI871470A0 (fi) 1987-04-03
DK170187A (da) 1987-10-05
AR242562A1 (es) 1993-04-30
ATE49752T1 (de) 1990-02-15
NZ219868A (en) 1989-02-24
NL8700791A (nl) 1987-11-02
IE870869L (en) 1987-10-04
NO172181C (no) 1993-06-16
CA1321393C (en) 1993-08-17
GB2188630A (en) 1987-10-07
DE3761485D1 (de) 1990-03-01
UA6344A1 (uk) 1994-12-29
BG60698B2 (en) 1995-12-29
AU573123B2 (en) 1988-05-26
DE3710457A1 (de) 1987-10-08
NO172181B (no) 1993-03-08
FI871470L (fi) 1987-10-05
NO871408D0 (no) 1987-04-03
KR950006710B1 (ko) 1995-06-21
PT84611A (en) 1987-05-01
YU44801B (en) 1991-02-28
LU86812A1 (fr) 1987-08-12
DK171708B1 (da) 1997-04-01
IL82101A0 (en) 1987-10-30
FI85017C (fi) 1992-02-25
KR870009998A (ko) 1987-11-30
IL82101A (en) 1991-01-31

Similar Documents

Publication Publication Date Title
JPH037668B2 (ja)
JP4319148B2 (ja) Ｓ−（−）−アムロジピンニコチネート及びその製造方法
US20070135488A1 (en) Amlodipine nicotinate and process for the preparation thereof
JP4319491B2 (ja) アムロジピンの有機酸塩
KR100538641B1 (ko) 암로디핀의 유기산염
EP1400512A1 (en) Crystalline organic acid salt of amlodipine
US6756390B2 (en) Organic acid salt of amlodipine
KR100496436B1 (ko) 암로디핀의 유기산염
JP2005538103A (ja) アムロジピンの有機酸塩
KR950007228B1 (ko) 암로디핀의 베실레이트염
KR100879972B1 (ko) 결정형의 암로디핀 유기산염
SI8710580A8 (sl) Postopek za pridobivanje benzolsulfonatne soli 3-etil-5-metil-2-(2-aminoetoksimetil)- 4-{2-klorofenil)-1.4-dihidro-6- metilpiridin-3.5-dikarboksilata

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080204

Year of fee payment: 17